Status:
COMPLETED
Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
20+ years
Brief Summary
The primary objective of this study is: To evaluate the real-world safety, specifically the incidence rates of hepatic toxicity, pyrexia, and resistance, of DCV/ASV dual therapy in Japanese patients c...
Detailed Description
Time Perspective: Other - For patients who are treated before the contract between Bristol-Myers Kabushiki Kaisha (BMKK) and the treating physician is initiated, patient data will be collected retrosp...
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
- Inclusion Criteria:
- Patients who are initiating DCV and ASV treatment for the first time under the approved indications, dosage, and administration will be included in this study
Exclusion
Key Trial Info
Start Date :
September 30 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 20 2017
Estimated Enrollment :
2974 Patients enrolled
Trial Details
Trial ID
NCT02250001
Start Date
September 30 2014
End Date
January 20 2017
Last Update
May 3 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Chuo-ku, Tokyo, Japan, 104-0033